Cognitive impairment and dementia in Parkinson's disease: Clinical features, diagnosis, and management

Frontiers in Neurology

Volumn MAY, Issue , 2012, Pages

  Meireles, Joana ^a,b   Massano, João ^a,b  

^a Centro Hospitalar Universitário de São João   (Portugal)

^b University of Porto   (Portugal)

Author keywords

Cognition; Dementia; Diagnosis; Diagnostic criteria; Mild cognitive impairment; Non motor symptoms; Parkinson's disease; Parkinson's disease dementia

Indexed keywords

EID: 84864237332     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2012.00088     Document Type: Article

References (193)

1. Aarsland, D., Andersen, K., Larsen, J. P., Perry, R., Wentzel-Larsen, T., Lolk, A., and Kragh-Sørensen, P. (2004). The rate of cognitive decline in Parkinson disease. Arch. Neurol. 61, 1906-1911.
2. Aarsland, D., Ballard, C., Larsen, J. P., and McKeith, I. (2001). A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int. J. Geriatr. Psychiatry 16, 528-536.
3. Aarsland, D., Cummings, J. L., and Larsen, J. P. (2001). Neuropsy-chiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int. J. Geriatr. Psychiatry 16, 184-191.
4. Aarsland, D., Litvan, I., and Larsen, J. P. (2001). Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 13, 42-49.
5. Aarsland, D., Ballard, C., Walker, Z., Bostrom, F., Alves, G., Kossakowski, K., Leroi, I., Pozo-Rodriguez, F., Minthon, L., and Londos, E. (2009). Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicen-tre trial. Lancet Neurol. 8, 613-618.
6. Aarsland, D., Bronnick, K., Williams-Gray, C., Weintraub, D., Marder, K., Kulisevsky, J., Burn, D., Barone, P., Pagonabarraga, J., Allcock, L., San-tangelo, G., Foltynie, T., Janvin, C., Larsen, J. P., Barker, R. A., and Emre, M. (2010). Mild cognitive impairment in Parkinson disease: a multi-center pooled analysis. Neurology 75, 1062-1069.
7. Aarsland, D., and Kurz, M. W. (2010). The epidemiology of dementia associated with Parkinson disease. J. Neurol. Sci. 289, 18-22.
8. Aarsland, D., Kvaloy, J. T., Anderson, K., Larsen, J. P., Tang, M. X., Lolk, A., Kragh-Sørensen, P., and Marder, K. (2007). The effect of age of onset of PD on risk of dementia. J. Neurol. 254, 38-45.
9. Aarsland, D., Larsen, J. P., Karlsen, K., Lim, N. G., and Tandberg, E. (1999). Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int. J. Geriatr. Psychiatry 14, 866-874.
10. Aarsland, D., Larsen, J. P., Tand-berg, E., and Laake, K. (2000). Predictors of nursing home placement in Parkinson's disease: a population based, prospective study. J. Am. Geriatr. Soc. 48, 938-942.
11. Aarsland, D., Zaccai, J., and Brayne, C. (2005). A systematic review of prevalence studies of dementia in Parkinson's disease. Mov. Disord. 20, 1255-1263.
12. Abbas, N., Lücking, C. B., Ricard, S., Dürr, A., Bonifati, V., De Michele, G., Bouley, S., Vaughan, J. R., Gasser, T., Marconi, R., Broussolle, E., Brefel-Courbon, C., Harhangi, B. S., Oos-tra, B. A., Fabrizio, E., Böhme, G. A., Pradier, L., Wood, N. W., Filla, A., Meco, G., Denefle, P., Agid, Y., and Brice, A. (1999). A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum. Mol. Genet. 8, 567-574.
13. Abou-Sleiman, P. M., Healy, D. G., Quinn, N., Lees, A. J., and Wood, N. W. (2003). The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann. Neurol. 54, 283-286.
14. Aharon-Peretz, J., Rosenbaum, H., and Gershoni-Baruch, R. (2004). Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashke-nazi Jews. N. Engl. J. Med. 351, 1972-1977.
15. Allan, L. M., Ballard, C. G., Allen, J., Murray, A., Davidson, A. W., McK-eith, I. G., and Kenny, R. A. (2007). Autonomic dysfunction in dementia. J. Neurol. Neurosurg. Psychiatr. 78, 671-677.
16. Almeida, M. R. (2012). Glucocere-brosidase involvement in Parkinson disease and other synucle-inopathies. Front. Neurol. 3:65. doi:10.3389/fneur.2012.00065
17. Alves, L., Correia, A. S. A., Miguel, R., Alegria, P., and Bugalho, P. (2012). Alzheimer's disease: a clinical practice-oriented review. Front. Neurol. 3:63. doi:10.3389/fneur.2012.00063
18. American Psychiatric Association. (1994). Diagnostic, and Statistical Manual of Mental Disorders, DSM-IV, 4th Edn. Arlington: American Psychiatric Press Inc.
19. Ballard, C. G., Aarsland, D., McKeith, I., O'Brien, J., Gray, A., Cormack, F., Burn, D., Cassidy, T., Starfeldt, R., Larsen, J. P., Brown, R., and Tovee, M. (2002). Fluctuations in attention in PD dementia vs DLB with parkin-sonism. Neurology 59, 1714-1720.
20. Barone, P., Aarsland, D., Burn, D., Emre, M., Kulisevsky, J., and Weintraub, D. (2011). Cognitive impairment in nondemented Parkinson's disease. Mov. Disord. 26, 2483-2495.
21. Barone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E., and Weintraub, D. (2010). Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 573-580.
22. Barton, B., Grabli, D., Bernard, B., Czer-necki, V., Goldman, J. G., Steb-bins, G., Dubois, B., and Goetz, C. G. (2012). Clinical validation of movement disorder society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov. Disord. 27, 248-253.
23. Benoit, M., Robert, P. H., Staccini, P., Brocker, P., Guerin, O., Lechowski, L., Vellas, B., and REAL. FR Group. (2005). One-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer's disease. The REAL. FR Study. J. Nutr. Health Aging 9, 95-99.
24. Boeve, B. F., Silber, M. H., Saper, C. B., Ferman, T. J., Dickson, D. W., Parisi, J. E., Benarroch, E. E., Ahlskog, J. E., Smith, G. E., Caselli, R. C., Tippman-Peikert, M., Olson, E. J., Lin, S. C., Young, T., Wszolek, Z., Schenck, C. H., Mahowald, M. W., Castillo, P. R., Del Tredici, K., and Braak, H. (2009). Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 130, 2770-2788.
25. Bohnen, N. I., and Albin, R. L. (2011). White matter lesions in Parkinson disease. Nat. Rev. Neurol. 7, 229-236.
26. Bonelli, R. M., and Cummings, J. L. (2008). Frontal-subcortical dementias. Neurologist 14, 100-107.
27. Bonelli, S. B., Ransmayr, G., Steffel-bauer, M., Lukas, T., Lampl, C., and Deibl, M. (2004). L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 63, 376-378.
28. Bonifati, V., Rohé, C. F., Breedveld, G. J., Fabrizio, E., De Mari, M., Tas-sorelli, C., Tavella, A., Marconi, R., Nicholl, D. J., Chien, H. F., Fincati, E., Abbruzzese, G., Marini, P., De Gaetano, A., Horstink, M. W., Maat-Kievit, J. A., Sampaio, C., Antonini, A., Stocchi, F., Montagna, P., Toni, V., Guidi, M., Dalla Libera, A., Tinazzi, M., De Pandis, F., Fabbrini, G., Gold-wurm, S., de Klein, A., Barbosa, E., Lopiano, L., Martignoni, E., Lam-berti, P., Vanacore, N., Meco, G., Oostra, B. A., and Italian Parkinson Genetics Network. (2005). Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65, 87-95.
29. Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211.
30. Brockmann, K., Srulijes, K., Hauser, A. K., Schulte, C., Csoti, I., Gasser, T., and Berg, D. (2011). GBA-associated PD presents with nonmotor characteristics. Neurology 77, 276-280.
31. Bronnick, K., Aarsland, D., and Larsen, J. P. (2005). Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia. Acta Psychiatr. Scand. 112, 201-207.
32. Bronnick, K., Emre, M., Lane, R., Tekin, S., and Aarsland, D. (2007). Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatr. 78, 1064-1068.
33. Burn, D. J., Rowan, E. N., Allan, L. M., Molloy, S., O'Brien, J. Y., and McKeith, I. J. (2006). Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J. Neurol. Neurosurg. Psychiatr. 77, 585-589.
34. Bymaster, F. P., Felder, C. C., Tzavara, E., Nomikos, G. G., Calligaro, D. O., and Mckinzie, D. L. (2003). Muscarinic mechanisms of antipsychotic atyp-icality. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 1125-1143.
35. Cahn-Weiner, D. A., Grace, J., Ott, B. R., Fernandez, H. H., and Friedman, J. H. (2002). Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's disease. Neuropsychiatry Neuropsychol. Behav. Neurol. 15, 79-87.
36. Cahn-Weiner, D.A., Williams, K., Grace, J., Tremont, G., Westervelt, H., and Stern R. A. (2003). Discrimination of dementia with lewy bodies from Alzheimer disease and Parkinson disease using the clock drawing test. Cogn. Behav. Neurol. 16, 85-92.
37. Calabresi, P., Di Filippo, M., Ghiglieri, V., Tambasco, N., and Picconi, B. (2010). Levodopa-induced dyskine-sias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol. 9, 1106-1117.
38. Caparros-Lefebvre, D., Pecheux, N., and Petit, V. (1995). Which factors predict cognitive decline in Parkinson's disease? J. Neurol. Neurosurg. Psychi-atr. 58, 51-55.
39. Caviness, J. N., Driver-Dunckley, E., Connor, D. J., Sabbagh, M. N., Hentz, J. G., Noble, B., Evidente, V. G. H., Shill, H., and Adler, C. H. (2007). Defining mild cognitive impairment in Parkinson's disease. Mov. Disord. 22, 1272-1277.
40. Caviness, J. N., Hentz, J. G., Evidente, V. G., Driver-Dunckley, E., Samanta, J., Mahant, P., Connor, D. J., Sab-bagh, M. N., Shill, H. A., and Adler, C. H. (2007). Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. Parkinsonism Relat. Disord. 13, 348-354.
41. Chaudhuri, K. R., and Schapira, A. H. V. (2009). Non-motor symptoms of Parkinson's disease: dopaminer-gic pathophysiology and treatment. Lancet Neurol. 8, 464-474.
42. Clark, L. N., Kartsaklis, L. A., Wolf Gilbert, R., Dorado, B., Ross, B. M., Kisselev, S., Verbitsky, M., Mejia-Santana, H., Cote, L. J., Andrews, H., Vonsattel, J. P., Fahn, S., Mayeux, R., Honig, L. S., and Marder, K. (2009). Association of glucocere-brosidase mutations with dementia with Lewy bodies. Arch. Neurol. 66, 578-583.
43. Cummings, J. L. (1988). The dementias of Parkinson's disease: prevalence, characteristics, neurobiology, and comparison with dementia of the Alzheimer type. Eur. Neurol. 28(Suppl. 1), 15-23.
44. Dalrymple-Alford, J. C., MacAskill, M. R., Nakas, C. T., Livingston, L., Graham, C., Crucian, G. P., Melzer, T. R., Kirwan, J., Keenan, R., Wells, S., Porter, R. J., Watts, R., and Anderson, T. J. (2010). The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 75, 1717-1725.
45. Darvesh, S., and Freedman, M. (1996). Subcortical dementia: a neurobe-havioral approach. Brain Cogn. 31, 230-249.
46. De Lau, L. M., Schipper, C. M., Hofman, A., Koudstaal, P. J., and Breteler, M. M. (2005). Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch. Neurol. 62, 1265-1269.
47. Dekker, M., Bonifati, V., van Swieten, J., Leenders, N., Galjaard, R. J., Snijders, P., Horstink, M., Heutink, P., Oostra, B., and van Duijn, C. (2003). Clinical features and neuroimaging of PARK7-linked parkinsonism. Mov. Disord. 18, 751-757.
48. Deng, H., Le, W., Guo, Y., Hunter, C. B., Xie, W., Huang, M., and Jankovic, J. (2006). Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J. Neurol. Sci. 251, 102-106.
49. DePaolo, J., Goker-Alpan, O., Samad-dar, T., Lopez, G., and Sidransky, E. (2009). The association between mutations in the lysosomal protein glucocerebrosidase and parkinson-ism. Mov. Disord. 24, 1571-1578.
50. Devos, D., Dujardin, K., Poirot, I., Moreau, C., Cottencin, O., Thomas, P., Destée, A., Bordet, R., and Defebvre, L. (2008). Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov. Dis-ord. 23, 850-857.
51. Diederich, N. J., Fénelon, G., Stebbins, G., and Goetz, C. G. (2009). Hallucinations in Parkinson disease. Nat. Rev. Neurol. 5, 331-342.
52. Domellöf, M. E., Elgh, E., and Fors-gren, L. (2011). The relation between cognition and motor dysfunction in drug-naive newly diagnosed patients with Parkinson's disease. Mov. Dis-ord. 26, 2183-2189.
53. Dubois, B., Burn, D., Goetz, C., Aars-land, D., Brown, R. G., Broe, G. A., Dickson, D., Duyckaerts, C., Cummings, J., Gauthier, S., Kor-czyn, A., Lees, A., Levy, R., Lit-van, I., Mizuno, Y., McKeith, I. G., Olanow, C. W., Poewe, W., Sampaio, C., Tolosa, E., and Emre, M. (2007). Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov. Disord. 22, 2314-2324.
54. Dujardin, K., Dubois, B., Tison, F., Durif, F., Bourdeix, I., Péré, J.-J., and Duhamel, A. (2010). Parkinson's disease dementia can be easily detected in routine clinical practice. Mov. Disord. 25, 2769-2776.
55. Elbaz, A., Ross, O. A., Ioannidis, J. P. A., Soto-Ortolaza, A. I., Moisan, F., and Aasly, J., Annesi, G., Bozi, M., Brighina, L., Chartier-Harlin, M.-C., Destée, A., Ferrarese, C., Ferraris, A., Gibson, J. M., Gispert, S., Hadji-georgiou, G. M., Jasinska-Myga, B., Klein, C., Krüger, R., Lambert, J. C., Lohmann, K., van de Loo, S., Loriot, M. A., Lynch, T., Mellick, G. D., Mutez, E., Nilsson, C., Opala, G., Puschmann, A., Quattrone, A., Sharma, M., Silburn, P. A., Stefa-nis, L., Uitti, R. J., Valente, E. M., Vilariño-Güell, C., Wirdefeldt, K., Wszolek, Z. K., Xiromerisiou, G., Maraganore, D. M., Farrer, M. J. and Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. (2011). Independent and joint effectsof the MAPTand SNCAgenes in Parkinson disease. Ann. Neurol. 69, 778-792.
56. Elizan, T. S., Sroka, H., Maker, H., Smith, H., and Yahr, M. D. (1986). Dementia in idiopathic Parkinson's disease: variables associated with its occurrence in 203 patients. J. Neural Transm. 65, 285-302.
57. Emre, M. (2010). "General features, mode of onset and course of dementia in Parkinson's disease," in Cognitive Impairment and Dementia in Parkinson's Disease, ed. M. Emre (Oxford: Oxford University Press), 15-22
58. Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., Poewe, W., Robil-lard, A., Rosa, M. M., Wolters, E., Quarg, P., Tekin, S., and Lane, R. (2004). Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351, 2509-2518.
59. Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dick-son, D. W., Gauthier, S., Goldman, J., Goetz, C., Korczyn, A., Lees, A., Levy, R., Litvan, I., McKeith, I., Olanow, W., Poewe, W., Quinn, N., Sam-paio, C., Tolosa, E., and Dubois, B. (2007). Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord. 22, 1689-1707.
60. Emre, M., Cummings, J.L., and Lane, R. M. (2007). Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J. Alzheimers Dis. 11, 509-519.
61. Emre, M., Tsolaki, M., Bonuccelli, U., Destée, A., Tolosa, E., Kutzel-nigg, A., Ceballos-Baumann, A., Zdravkovic, S., Bladström, A., Jones, R., and 11018 Study Investigators. (2010). Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 969-977.
62. Engelborghs, S., Maertens, K., Nagels, G., Vloeberghs, E., Mariën, P., Symons, A., Ketels, V., Estercam, S., Somers, N., and De Deyn, P. P. (2005). Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. Int. J. Geriatr. Psychiatry 20, 1028-1037.
63. Evans, J. R., Mason, S. L., Williams-Gray, C. H., Foltynie, T., Brayne, C., Robbins, T. W., and Barker, R. A. (2011). The natural history of treated Parkinson's disease in an incident, community based cohort. J. Neurol. Neurosurg. Psychiatr. 82, 1112-1118.
64. Farrer, M., Chan, P., Chen, R., Tan, L., Lincoln, S., Hernandez, D., Forno, L., Gwinn-Hardy, K., Petrucelli, L., Hussey, J., Singleton, A., Tanner, C., Hardy, J., and Langston, J. W. (2001). Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50, 293-300.
65. Fenelon, G., Mahieux, F., Huon, R., and Ziegler, M. (2000). Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123, 733-745.
66. Fernandez, H. H., Donnelly, E. M., and Friedman, J. H. (2004). Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov. Disord. 19, 831-833.
67. Ferrini-Strambi, L., Di Gioia, M. R., Castronovo, V., Oldani, A., Zucconi, M., and Cappa, S. F. (2004). Neu-ropsychological assessment in idio-pathic REM sleep behavior disorder. Neurology 61, 41-45.
68. Foltynie, T., Brayne, C. E. G., Robbins, T. W., and Barker, R. A. (2004). The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 127, 1-11.
69. Frank, E. M., McDade, H. L., and Scott, W. K. (1996). Naming in dementia secondary to Parkinson's, Hunt-ington's, and Alzheimer's diseases. J. Commun. Disord. 29, 183-197.
70. Frauscher, B., Iranzo, A., Högl, B., Casanova-Molla, J., and Salamero, M., Gschliesser, V., Tolosa, E., Poewe, W., Santamaria, J. SIN-BAR (Sleep Innsbruck Barcelona group). (2008). Quantification of electromyographic activity during REM sleep in multiple muscles in REM sleep behavior disorder. Sleep 31, 724-731.
71. Gagnon, J. F., Vendette, M., Postuma, R. B., Desjardins, C., Massicotte-Marquez, J., Panisset, M., and Mont-plaisir, J. (2009). Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease. Ann. Neurol. 66, 39-47.
72. Galimberti, D., and Scarpini, E. (2012). Genetics of frontotemporal lobar degeneration. Front. Neurol. 3:52. doi:10.3389/fneur.2012.00052
73. Gareri, P., De Fazio, P., Russo, E., Marigliano, N., De Fazio, S., and De Sarro, G. (2008). The safety of cloza-pine in the elderly. Expert Opin. Drug Saf. 7, 525-538.
74. Gasser, T. (2007). Update on the genetics of Parkinson's disease. Mov. Disord. 22(Suppl. 17), S343-S350.
75. Giladin, N., Treves, T. A., Paleacu, D., Shabtai, H., Orlov, Y., Kandinov, B., Simon, E. S., and Korczyn, A. D. (2000). Risk factors for dementia and depression and psychosis in long standing Parkinson's disease. J. Neural Transm. 107, 59-71.
76. Gjerstad, M. D., Aarsland, D., and Larsen, J. P. (2002). Development of daytime somnolence over time in Parkinson's disease. Neurology 18, 1544-1546.
77. Goetz, C. G. (2011). The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb. Perspect. Med. 1, a008862.
78. Goetz, C. G., Emre, M., and Dubois, B. (2008). Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann. Neurol. 64, S81-S92.
79. Goldman, J. S., Hahn, S. E., Catania, J. W., LaRusse-Eckert, S., But-son, M. B., Rumbaugh, M., Strecker, M. N., Roberts, J. S., Burke, W., Mayeux, R., and Bird, T., American College of Medical Genetics and the National Society of Genetic Counselors. (2011). Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet. Med. 13, 597-605.
80. Gouider-Khouja, N., Larnaout, A., Amouri, R., Sfar, S., Belal, S., Ben Hamida, C., Ben Hamida, M., Hat-tori, N., Mizuno, Y., and Hentati, F. (2003). Autosomal recessive parkin-sonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study. Parkinson-ism Relat. Disord. 9, 247-251.
81. Hanes, K. R., Pantelis, C., Andrewes, D. G., and Chiu, E. (1996). Brief report: bradyphrenia in Parkinson's disease, Huntington's disease, and schizophrenia. Cogn. Neuropsychiatry 1, 165-170.
82. Hawkes, C. H., Del Tredici, K., and Braak, H. (2010). A timeline for Parkinson's disease. Parkinsonism Relat. Disord. 16, 79-84.
83. Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., Ferreira, J. J., Tolosa, E., Kay, D. M., Klein, C., Williams, D. R., Marras, C., Lang, A. E., Wszolek, Z. K., Berciano, J., Schapira, A. H., Lynch, T., Bhatia, K. P., Gasser, T., Lees, A. J., Wood, N. W., and International LRRK2 Consortium. (2008). Phenotype, genotype, and worldwide genetic pene-trance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 7, 583-590.
84. Hely, M. A., Morris, J. G., Reid, W. G., O'Sullivan, D. J., Williamson, P. M., Rail, D., Broe, G. A., and Margrie, S. (1994). The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J. Neurol. Neurosurg. Psychiatr. 57, 903-910.
85. Hely, M. A., Morris, J. G., Reid, W. G., and Trafficante, R. (2005). Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord. 20, 190-199.
86. Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M., and Morris, J. G. (2008). The Sydney multicen-ter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837-844.
87. Henry, J. D., and Crawford, J. R. (2004). Verbal fluency deficits in Parkinson's disease: a meta-analysis. J. Int. Neuropsychol. Soc. 10, 608-622.
88. Higginson, C. I., Wheelock, V. L., Carroll, K. E., and Sigvardt, K. A. (2005). Recognition memory in Parkinson's disease with and without dementia: evidence inconsistent with the retrieval deficit hypothesis. J. Clin. Exp. Neuropsychol. 27, 516-528.
89. Hirono, N., Mori, E., Tanimukai, S., Kazui, H., Hashimoto, M., Hani-hara, T., and Imamura, T. (1999). Distinctive neurobehavioral features among neurodegenerative dementias. J. Neuropsychiatry Clin. Neu-rosci. 11, 498-503.
90. Hobson, P., Meara, J., and Ishihara-Paul, L. (2010). The estimated life expectancy in a community cohort of Parkinson's disease patients with and without dementia, compared with the UK population. J. Neurol. Neurosurg. Psychiatr. 81, 1093-1098.
91. Hughes, T.A., Ross, H. F., Musa, S., Bhat-tacherjee, S., Nathan, R. N., Mind-ham, R. H., and Spokes, E. G. (2000). A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 54, 1596-1602.
92. Ibáñez, P., Lesage, S., Lohmann, E., Thobois, S., De Michele, G., Borg, M., Agid, Y., Dürr, A., Brice, A., and French Parkinson's Disease Genetics Study Group. (2006). Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 129, 686-694.
93. Idiaquez, J., Benarroch, E. E., Rosales, H., Milla, P., and Ríos, L. (2007). Autonomic and cognitive dysfunction in Parkinson's disease. Clin. Auton. Res. 17, 93-98.
94. Iranzo, A. (2011). Sleep-wake changes in the premotor stage of Parkinson disease. J. Neurol. Sci. 310, 283-285.
95. Iranzo, A., Molinuevo, J. L., Santa-maría, J., Serradell, M., Martí, M. J., Valldeoriola, F., and Tolosa, E. (2006). Rapid-eye-movement sleep behavior disorder as an early marker for a neurodegenerative disease: a descriptive study. Lancet Neurol. 5, 572-577.
96. Iranzo, A., Santamaría, J., Rye, D. B., Valldeoriola, F., Martí, M. J., Muñoz, E., Vilaseca, I., and Tolosa, E. (2005). Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 65, 247-252.
97. Janvin, C. C., Larsen, J. P., Salmon, D. P., Galasko, D., Hugdahl, K., and Aars-land, D. (2006). Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with Lewy bodies and Alzheimer's disease. Mov. Disord. 21, 337-342.
98. Jeannerod, M., and Jacob, P. (2005). Visual cognition: a new look at the two-visual systems model. Neu-ropsychologia 43, 301-312.
99. Joyce, J. N., Ryoo, H. L., Beach, T. B., Caviness, J. N., Stacy, M., Gure-vich, E. V., Reiser, M., and Adler, C. H. (2002). Loss of response to lev-odopa in Parkinson's disease and cooccurrence with dementia: role of D3 and not D2 receptors. Brain Res. 955, 138-152.
100. Kägi, G., Klein, C., Wood, N. W., Schneider, S. A., Pramstaller, P. P., Tadic, V., Quinn, N. P., van de Warrenburg, B. P., and Bhatia K. P. (2010). Non-motor symptoms in Parkin gene-related parkinsonism. Mov. Disord. 25, 1279-1284.
101. Kai, T., Asai, T., Sakuma, K., Koeda, T., and Nakashima, K. (2005). Quantitative electroencephalogram analysis in dementia with Lewy Bodies and Alzheimer disease. J. Neurol. Sci. 237, 89-95.
102. Kasten, M., Kertelge, L., Brüggemann, N., van der Vegt, J., Schmidt, A., Tadic, V., Buhmann, C., Steinlech-ner, S., Behrens, M. I., Ramirez, A., Binkofski, F., Siebner, H., Raspe, H., Hagenah, J., Lencer, R., and Klein, C. (2010). Nonmotor symptoms in genetic Parkinson disease. Arch. Neurol. 67, 670-676.
103. Kehagia, A. A., Barker, R. A., and Rob-bins, T. W. (2010). Neuropsycho-logical and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 9, 1200-1213.
104. Kertesz, A. (2003). Pick complex: an integrative approach to frontotem-poral dementia: primary progressive aphasia, corticobasal degeneration, and progressive supranuclear palsy. Neurologist 9, 311-317.
105. Khan, N. L., Graham, E., Critchley, P., Schrag, A. E., Wood, N. W., Lees, A. J., Bhatia, K. P., and Quinn, N. (2003). Parkin disease: a phenotypic study of a large case series. Brain 126, 1279-1292.
106. Klein, C., Pramstaller, P. P., Kis, B., Page, C C., Kann, M., Leung, J., Woodward, H., Castellan, C. C., Scherer, M., Vieregge, P., Breakefield, X. O., Kramer, P. L., and Ozelius, L. J. (2000). Parkin deletions in a family with adultonset, tremordominant parkinsonism: expanding the phenotype. Ann. Neurol. 48, 65-71.
107. Klein, C., Schneider, S. A., and Lang, A. E. (2009). Hereditary parkinsonism: Parkinson disease look alikes - an algorithm for clinicians to "PARK" genes and beyond. Mov. Disord. 24, 2042-2058.
108. Klein, C., and Westenberger, A. (2012). Genetics of Parkinson's disease. Cold Spring Harb. Perspect. Med. 2, a008888.
109. Kramer, J. H., and Duffy, J. M. (1996). Aphasia, apraxia, and agnosia in the diagnosis of dementia. Dementia 7, 23-26.
110. Kudlicka, A., Clare, L., and Hindle, J. V. (2011). Executive functions in Parkinson's disease: systematic review and meta-analysis. Mov. Dis-ord. 26, 2305-2315.
111. Labbate, L. A., Fava, M., and Rosen-baum, J. F. and Arana G. W. (2009). Handbook of Psychiatric Drug Therapy, 6th Edn. Philadelphia: Lippin-cott Williams & Wilkins.
112. Leentjens, A. F., Vreeling, F. W., Lui-jckx, G. J., and Verhey, F. R. (2003). SSRIs in the treatment of depression in Parkinson's disease. Int. J. Geriatr. Psychiatry 18, 552-554.
113. Leutenegger, A. L., Salih, M. A., Ibáñez, P., Mukhtar, M. M., Lesage, S., Arabi, A., Lohmann, E., Dürr, A., Ahmed, A. E., and Brice, A. (2006). Juvenile-onset parkinsonism as a result of the first mutation in the adenosine triphosphate orientation domain of PINK1. Arch. Neurol. 63, 1257-1261.
114. Levy, G., Tang, M. X., Louis, E. D., Côté, L. J., Alfaro, B., Mejia, H., Stern, Y., and Marder, K. (2002). The association of incident dementia with mortality in PD. Neurology 59, 1708-1713.
115. Lim, S. Y., Fox, S. H., and Lang, A. E. (2009). Overview of the extranigral aspects of Parkinson disease. Arch. Neurol. 66, 167-172.
116. Litvan, I., Aarsland, D., Adler, C. H., Goldman, J. G., Kulisevsky, J., Mol-lenhauer, B., Rodriguez-Oroz, M. C., Tröster, A. I., and Weintraub, D. (2011). MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov. Disord. 15, 1814-1824.
117. Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams-Gray, C. H., Aarsland, D., Kulisevsky, J., Rodriguez-Oroz, M. C., Burn, D. J., Barker, R.A., and Emre, M. (2012). Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 24, 489-495.
118. Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., Agid, Y., Brice, A., French Parkinson's Disease Genetics Study Group, and European Consortium on Genetic Susceptibility in Parkinson's Disease. (2000). Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 342, 1560-1567.
119. Mamikonyan, E., Moberg, P. J., Siderowf, A., Duda, J. E., Have, T. T., Hurtig, H. I., Stern, M. B., and Wein-traub, D. (2009). Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat. Disord. 15, 226-231.
120. Martinez-Martin, P., Falup-Pecurariu, C., Rodriguez-Blazquez, C., Serrano-Dueñas, M., Carod Artal, F. J., Rojo Abuin, J. M., and Aarsland, D. (2011). Dementia associated with Parkinson's disease: applying the Movement Disorder Society Task Force criteria. Parkinsonism Relat. Disord. 17, 621-624.
121. Massano, J., and Bhatia, K. P. (2012). Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harb. Perspect. Med. doi:10.1101/cshperspect.000870. (in press).
122. Massano, J., and Garrett, C. (2012). Deep brain stimulation and cognitive decline in Parkinson's disease: a clinical review. Front. Neurol. 3:66. doi:10.3389/fneur.2012.00066
123. McKeith, I. (2005). Dementia with Lewy bodies and Parkinson's disease with dementia: where two worlds collide. Pract. Neurol. 7, 374-382.
124. McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feld-man, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., Aars-land, D., Arai, H., Ballard, C. G., Boeve, B., Burn, D. J., Costa, D., Del Ser, T., Dubois, B., Galasko, D., Gauthier, S., Goetz, C. G., Gomez-Tortosa, E., Halliday, G., Hansen, L. A., Hardy, J., Iwatsubo, T., Kalaria, R. N., Kaufer, D., Kenny, R. A., Korczyn, A., Kosaka, K., Lee, V. M., Lees, A., Litvan, I., Londos, E., Lopez, O. L., Minoshima, S., Mizuno, Y., Molina, J. A., Mukaetova-Ladinska, E. B., Pasquier, F., Perry, R. H., Schulz, J. B., Trojanowski, J. Q., Yamada, M. and Consortium on DLB. (2005). Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863-1872.
125. Menza, M., Dobkin, R. D., Marin, H., Mark, M. H., Gara, M., Buyske, S., Bienfait, K., and Dicke, A. (2009). A controlled trial of antidepressants in patients with Parkinson's disease and depression. Neurology 72, 886-892.
126. Menza, M. A., Robertson, H. D., and Bonapace, A. S. (1993). Parkinson's disease and anxiety: comorbidity with depression. Biol. Psychiatry 34, 465-470.
127. Metzler-Baddeley, C. (2007). A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer's disease and Parkinson's disease with dementia. Cortex 43, 583-600.
128. Morley, J. F., Xie, S. X., Hurtig, H. I., Stern, M. B., Colcher, A., Horn, S., Dahodwala, N., Duda, J. E., Weintraub, D., Chen-Plotkin, A. S., Van Deerlin, V., Falcone, D., and Siderowf, A. (2012). Genetic influences on cognitive decline in Parkinson's disease. Mov. Disord. 27, 512-518.
129. Mosimann, U. P., Mather, G., and Wesnes, K. A. (2004). Visual perception in Parkinson disease dementia and dmentia with Lewy bodies. Neurology 63, 2091-2096.
130. Muslimovic, D., Post, B., Speelman, J. D., and Schmand, B. (2005). Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65, 1239-1245.
131. Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lach-mann, R. H., Li, A., Holton, J., Guer-reiro, R., Paudel, R., Segarane, B., Singleton, A., Lees, A., Hardy, J., Houlden, H., Revesz, T., and Wood, N. W. (2009). Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132, 1783-1794.
132. Nishioka, K., Ross, O. A., Vilariño-Güell, C., Cobb, S. A., Kachergus, J. M., Mann, D. M., Snowden, J., Richardson, A. M., Neary, D., Robinson, C. A., Rajput, A., Papapetropoulos, S., Mash, D. C., Pahwa, R., Lyons, K. E., Wszolek, Z. K., Dickson, D. W., and Farrer, M. J. (2011). Glucocerebrosi-dase mutations in diffuse Lewy body disease. Parkinsonism Relat. Disord. 17, 55-57.
133. Noe, E., Marder, K., Bell, K. L., Jacobs, D. M., Manly, J. J., and Stern, Y. (2004). Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov. Disord. 19, 60-67.
134. Olson, E. J., Boeve, B. F., and Silber, M. H. (2000). Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 123, 331-339.
135. O'Mahony, D., Rowan, M., Feely, J., O'Neill, D., Walsh, J. B., and Coakley, D. (1993). Parkinson's dementia and Alzheimer's dementia: an evoked potential comparison. Gerontology 39, 228-240.
136. Ondo, W. G., Tintner, R., Voung, K. D., Lai, D., and Ringholz, G. (2005). Double-blind, placebo controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov. Disord. 20, 958-963.
137. Owen, A. M., James, M., Leigh, P. N., Summers, B. A., Marsden, C. D., Quinn, N. P., Lange, K. W., and Rob-bins, T. W. (1992). Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 115, 1727-1751.
138. Pai, M. C., and Chan, S. H. (2001). Education and cognitive decline in Parkinson's disease: a study of 102 patients. Acta Neurol. Scand. 103, 243-247.
139. Papapetropoulos, S., Ellul, J., Poly-chronopoulos, P., and Chroni, E. (2004). A registry-based, case- control investigation of Parkinson's disease with and without cognitive impairment. Eur. J. Neurol. 11, 347-351.
140. Parkinson, J. (1817). An Essay on the Shaking Palsy. London: Sherwood, Neely, and Jones.
141. Pickering, R. M., Grimbergen, Y. A., Rigney, U., Ashburn, A., Mazibrada, G., Wood, B., Gray, P., Kerr, G., and Bloem, B. R. (2007). A meta-analysis of six prospective studies of falling in Parkinson's disease. Mov. Disord. 22, 1892-1900.
142. Pillon, B., Deweer, B., Agid, Y., and Dubois, B. (1993). Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch. Neurol. 50, 374-349.
143. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Sten-roos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropou-los, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
144. Rabey, J. M., Prokhorov, T., Miniovitz, A., Dobronevsky, E., and Klein, C. (2007). Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov. Disord. 22, 313-318.
145. Rajput, A. H., Voll, A., Rajput, M. L., Robinson, C. A., and Rajput, A. (2009). Course in Parkinson disease subtypes: a 39-year clinicopatho-logic study. Neurology 73, 206-212.
146. Raskin, S., and Durst, R. (2010). Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments. Med. Hypotheses 75, 544-546.
147. Reid, W. G., Broe, G. A., Hely, M. A., Morris, J. G., Williamson, P. M., O'Sullivan, D. J., Rail, D., Genge, S., and Moss, N. G. (1989). The neu-ropsychology of de novo patients with idiopathic Parkinson's disease: the effects of age of onset. Int. J. Neurosci. 48, 205-217.
148. Rogers, D., Lees, A. J., Smith, E., Trimble, M., and Stern, G. M. (1987). Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study. Brain 110, 761-776.
149. Salmon, D. P., and Filoteo, J. V. (2007). Neuropsychology of cortical versus subcortical dementia syndromes. Semin. Neurol. 27, 7-21.
150. Savica, R., Rocca, W. A., and Ahlskog, J. E. (2010). When does Parkinson disease start? Arch. Neurol. 67, 798-801.
151. Schapira, A. H., and Tolosa, E. (2010). Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat. Rev. Neurol. 6, 309-317.
152. Schrag, A., Ben-Shlomo, Y., Brown, R., Marsden, C. D., and Quinn, N. (1998).Young-onset Parkinson's disease revisited - clinical features, natural history, and mortality. Mov. Disord. 13, 885-894.
153. Schrag, A., and Schott, J. M. (2006). Epi-demiological, clinical, and genetic characteristics of early-onset parkin-sonism. Lancet Neurol. 5, 355-363.
154. Selikhova, M., Williams, D. R., Kemp-ster, P. A., Holton, J. L., Revesz, T., and Lees, A. J. (2009). A clinico-pathological study of subtypes in Parkinson's disease. Brain 132, 2947-2957.
155. Setó-Salvia, N., Clarimón, J., Pago-nabarraga, J., Pascual-Sedano, B., Campolongo, A., Combarros, O., Mateo, J. I., Regaña, D., Martínez-Corral, M., Marquié, M., Alcolea, D., Suárez-Calvet, M., Molina-Porcel, L., Dols, O., Gómez-Isla, T., Blesa, R., Lleó, A., and Kulisevsky, J. (2011). Dementia risk in Parkinson disease: disentangling the role of MAPT hap-lotypes. Arch. Neurol. 68, 359-364.
156. Setó-Salvia, N., Pagonabarraga, J., Houlden, H., Pascual-Sedano, B., Dols-Icardo, O., Tucci, A., Paisán-Ruiz, C., Campolongo, A., Antón-Aguirre, S., Martín, I., Muñoz, L., Bufill, E., Vilageliu, L., Grinberg, D., Cozar, M., Blesa, R., Lleó, A., Hardy, J., Kulisevsky, J., and Clarimón, J. (2012). Glucocerebrosi-dase mutations confer a greater risk of dementia during Parkinson's disease course. Mov. Disord. 3, 393-399.
157. Shachar, T., Lo Bianco, C., Recchia, A., Wiessner, C., Raas-Rothschild, A., and Futerman, A. H. (2011). Lyso-somal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov. Disord. 26, 1593-1604.
158. Shotbolt, P., Samuel, M., Fox, C., and David, A. S. (2009). A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr. Dis. Treat. 5, 327-332.
159. Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Bar-bosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C. M., Clark, L. N., Condroyer, C., De Marco, E. V., Dürr, A., Eblan, M. J., Fahn, S., Farrer, M. J., Fung, H. C., Gan-Or, Z., Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, A. E., Lee-Chen, G. J., Lesage, S., Marder, K., Mata, I. F., Mirelman, A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L. V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E. K., Tayebi, N., Toda, T., Troiano, A. R., Tsuji, S., Witt-stock, M., Wolfsberg, T. G., Wu, Y. R., Zabetian, C. P., Zhao, Y., and Ziegler, S. G. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361, 1651-1661.
160. Spira, P. J., Sharpe, D. M., Halliday, G., Cavanagh, J., and Nicholson, G. A. (2001). Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 49, 313-319.
161. Starkstein, S. E., Sabe, L., and Petracca, G. (1996). Neuropsychological and psychiatric differences between Alzheimer's disease and Parkinson's disease with dementia. J. Neurol. Neurosurg. Psychiatr. 61, 381-387.
162. Steinlechner, S., Stahlberg, J., Völkel, B., Djarmati, A., Hagenah, J., Hiller, A., Hedrich, K., König, I., Klein, C., and Lencer, R. (2007). Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations. J. Neurol. Neurosurg. Psychiatr. 78, 532-535.
163. Stern, Y., Marder, K., Tang, M. X., and Mayeux, R. (1993). Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 43, 1690-1692.
164. Stuss, D. T. (2011). Functions of the frontal lobes: relation to executive functions. J. Int. Neuropsychol. Soc. 17, 759-765.
165. Taipa, R., Pinho, J., and Melo-Pires, M. (2012). Clinico-pathological correlations of the most common neurodegenerative dementias. Front. Neurol. 3:68. doi:10.3389/ fneur.2012.00068
166. Tan, E. K., and Jankovic, J. (2006). Genetic testing in Parkinson disease: promises and pitfalls. Arch. Neurol. 63, 1232-1237.
167. Terzaghi, M., Sinforiani, E., and Zuc-chella, C. (2008). Cognitive performance in REM sleep behaviour disorder: a possible early marker of neurodegenerative disease? Sleep Med. 9, 343-351.
168. The Parkinson Study Group. (1999). Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med. 340, 757-763.
169. Tolosa, E., Gaig, C., Santamaría, J., and Compta, Y. (2009). Diagnosis and the premotor phase of Parkinson disease. Neurology 27, S12-S20.
170. Tröster, A. I. (2008). Neuropsychologi-cal characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for "mild cognitive impairment" and biomarkers. Neuropsychol. Rev. 18, 103-119.
171. Trotta, L., Guella, I., Soldà, G., Sironi, F., Tesei, S., Canesi, M., Pezzoli, G., Goldwurm, S., Duga, S., and Asselta, R. (2012). SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population. Parkinsonism Relat. Disord. 18, 257-162.
172. Turner, M. A., Moran, N. F., and Kopelman, M. D. (2002). Subcorti-cal dementia. Br. J. Psychiatry 180, 148-151.
173. Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., Albanese, A., Nussbaum, R., González-Maldonado, R., Deller, T., Salvi, S., Cortelli, P., Gilks, W. P., Latchman, D. S., Harvey, R. J., Dallapiccola, B., Auburger, G., and Wood, N. W. (2004). Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160.
174. Valente, E. M., Bentivoglio, A. R., Dixon, P. H., Ferraris, A., Ialongo, T., Frontali, M., Albanese, A., and Wood, N. W. (2001). Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Genet. 68, 895-900.
175. Valente, E. M., Brancati, F., Ferraris, A., Graham, E. A., Davis, M. B., Breteler, M. M., Gasser, T., Bonifati, V., Bentivoglio, A. R., De Michele, G., Dürr, A., Cortelli, P., Wassilowsky, D., Harhangi, B. S., Rawal, N., Caputo, V., Filla, A., Meco, G., Oostra, B. A., Brice, A., Albanese, A., Dallapiccola, B., Wood, N. W. and European Consortium on Genetic Susceptibility in Parkinson's Disease. (2002). PARK6-linked parkinsonism occurs in several European families. Ann. Neurol. 51, 14-18.
176. van Duijn, C. M., Dekker, M. C., Boni-fati, V., Galjaard, R. J., Houwing-Duistermaat, J. J., Snijders, P. J., Testers, L., Breedveld, G. J., Horstink, M., Sandkuijl, L. A., van Swieten, J. C., Oostra, B. A., and Heutink, P. (2001). Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am. J. Hum. Genet. 69, 629-634.
177. Velayati, A., Yu, W. H., and Sidransky, E. (2010). The role of glucocerebrosi-dase mutations in Parkinson disease and Lewy body disorders. Curr. Neurol. Neurosci. Rep. 10, 190-198.
178. Wattjes, M. P. (2011). Structural MRI. Int. Psychogeriatr. 23(Suppl. 2), S13-S24.
179. Weintraub, D., and Burn, D. J. (2011). Parkinson's disease: the quintessential neuropsychiatric disorder. Mov. Disord. 26, 1022-1031.
180. Weintraub, D., Taraborelli, D., Morales, K. H., Duda, J. E., Katz, I. R., and Stern, M. B. (2006). Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study. J. Neuropsychiatry Clin. Neu-rosci. 18, 377-383.
181. Weintraub, S., Wicklund, A. H., and Salmon, D. P. (2012). The neu-ropsychological profile of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006171.
182. Wermuth, L., Sorensen, P. S., Timm, S., Christensen, B., Utzon, N. P., Boas, J., Dupont, E., Hansen, E., Magnussen, I., Mikkelsen, B., Worm-Petersen, J., Lauritzen, L., Bayer, L., and Bech, P. (1998). Depression in idiopathic Parkinson's disease treated with citalopram: a placebo-controlled trial. Nord. J. Psychiatry 52, 163-169.
183. Wickremaratchi, M. M., Majounie, E., Morris, H. R., Williams, N. M., Lewis, H., Gill, S. S., Khan, S., Heywood, P., Hardy, J., Wiles, C. M., Singleton, A. B., and Quinn, N. P. (2009). Parkin-related disease clinically diagnosed as a pallido-pyramidal syndrome. Mov. Disord. 24, 138-140.
184. Williams, D. R., and Lees, A. J. (2005). Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol. 4, 605-610.
185. Williams-Gray, C. H., Evans, J. R., Goris, A., Foltynie, T., Ban, M., Robbins, T. W., Brayne, C., Kolachana, B. S., Weinberger, D. R., Sawcer, S. J., and Barker, R. A. (2009). The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 132, 2958-2969.
186. Winblad, B., Cummings, J., Andreasen, N., Grossberg, G., Onofrj, M., Sadowsky, C., Zechner, S., Nagel, J., and Lane, R. (2007). A six-month double-blind, randomized, placebo-controlled study of a trans-dermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry 22, 456-567.
187. Winge, K., and Fowler, C. J. (2006). Bladder dysfunction in Parkinson-ism: mechanisms, prevalence, symptoms, and management. Mov. Dis-ord. 21, 737-745.
188. Wood, B. H., Bilclough, J. A., Bowron, A., and Walker, R. W. (2002). Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study. J. Neurol. Neurosurg. Psychiatr. 72, 721-725.
189. Wszolek, Z. K., Pfeiffer, R. F., Tsuboi, Y., Uitti, R. J., McComb, R. D., Stoessl, A. J., Strongosky, A. J., Zimprich, A., Müller-Myhsok, B., Farrer, M. J., Gasser, T., Calne, D. B., and Dickson, D. W. (2004). Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62, 1619-1622.
190. Zarranz, J. J., Alegre, J., Gómez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Muñoz, D. G., and de Yebenes, J. G. (2004). The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173.
191. Zaluska, M., and Dyduch, A. (2011). Bupropion in the treatment of depression in Parkinson's disease. Int. Psychogeriatr. 23, 325-327.
192. Zesiewicz, T. A., Sullivan, K. L., Arnulf, I., Chaudhuri, K. R., Morgan, J. C., Gronseth, G. S., Miyasaki, J., Iver-son, D. J., and Weiner, W. J. (2010). Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 74, 924-931.
193. Zoldan, J., Friedberg, G., Livneh, M.,and Melamed, E. (1995). Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 45, 1305-1308.